Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting

Urology

Volumn 65, Issue 2, 2005, Pages 300-305

  Mochtar, C A ^a   Kiemeney, L A L M ^b   Laguna, M P ^b   Van Riemsdijk, M M ^b   Barnett, G S ^b   Debruyne, F M J ^b   De La Rosette, J J M C H ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RESIDUAL URINE; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT OBSTRUCTION; URINE FLOW RATE;

EID: 13844250633     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.09.030     Document Type: Article

References (19)

1. M. Emberton, G.L. Andriole, J. de la Rosette BPH a progressive disease of aging men Urology 61 2003 267 273
2. C.G. Roehrborn, J.D. McConnell, M. Lieber Serum prostate-specific antigen is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia Urology 53 1999 473 480
3. C.G. Roehrborn, P. Boyle, D. Bergner Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate results of a four-year, randomized trial comparing finasteride versus placebo Urology 54 1999 662 669
4. M.J. Marberger, J.T. Andersen, J.C. Nickel Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention Eur Urol 38 2000 563 568
5. S. Kaplan, D. Garvin, P. Gilhooly for the PLESS Study Group Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride Urology 56 2000 610 616
6. C.G. Roehrborn, J.D. McConnell, B. Saltzman Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes Eur Urol 42 2002 1 6
7. J.J. de la Rosette, G. Alivizatos, S. Madersbacher EAU guidelines on benign prostatic hyperplasia (BPH) Eur Urol 40 2001 256 263
8. C.G. Roehrborn, G. Bartsch, R. Kirby Guidelines for the diagnosis and treatment of benign prostatic hyperplasia a comparative, international overview Urology 58 2001 642 650
9. R.C. Flanigan, D.J. Reda, J.H. Wasson 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia a Department of Veterans Affairs Cooperative Study J Urol 160 1998 12 17
10. N.R. Netto Jr, M.L. de Lima, M.R. Netto Evaluation of patients with bladder outlet obstruction and mild International Prostate Symptom Score followed up by watchful waiting Urology 53 1999 314 316
11. J.J.M.C.H. de la Rosette, B.B.M. Kortmann, C. Rossi Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms J Urol 167 2002 1734 1739
12. J.D. McConnell, C.G. Roehrborn, O.M. Bautista for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
13. P. Narayan, C.P. Evans, T. Moon Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia J Urol 170 2003 498 502
14. C.G. Roehrborn, J.D. McConnell Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia P.C. Walsh A.B. Retik E.D. Vaughan Jr Campbell's Urology 8th ed 2002 WB Saunders Philadelphia 1297 1335
15. H.J. Stoevelaar, C. Van de Beek, A.F. Casparie Treatment choice for benign prostatic hyperplasia a matter of urologist preference? J Urol 161 1999 133 138
16. B.J. Hansen, H.H. Meyhoff, J. Nordling for the ALFECH Study Group Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia Scand J Urol Nephrol 30 1996 373 377
17. S.M. Sech, J.D. Montoya, P.A. Bernier The so-called placebo effect in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring Urology 51 1998 242 250
18. C.G. Roehrborn, P. Boyle, A.L. Gould Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia Urology 53 1999 581 589
19. C.A. Mochtar, L.A. Kiemeney, M.M. van Riemsdijk Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia Eur Urol 44 2003 695 700